MedTrace Logo

One Touch VerioIQ US Clinical Outcomes Study

NCT01627899 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2018-08-02

Study results available
· View outcomes & findings →

Summary

Evaluation of the clinical benefits of One Touch VerioIQ system

Conditions

Interventions

DEVICE

One Touch VerioIQ Blood Glucose Monitor

BGM with pattern alert technology and with associated pattern guide

Sponsors & Collaborators

  • LifeScan

    lead INDUSTRY

Principal Investigators

  • Priscilla Hollander, MD · Baylor Endocrine Center, 3600 Gaston Avenue Wadley Tower, Suite 656, Dallas, TX 75246, Phone: 214-820-3466, Fax: 214-820-3468

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-01
Primary Completion
2013-05-01
Completion
2013-07-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01627899 on ClinicalTrials.gov